CAMBRIDGE, Mass., September 5, 2023 – CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression, today announced that its leadership team will participate in the following upcoming industry and investor conferences in September 2023. CAMP4’s RAP Platform™ and pioneering approach enable the discovery and development of our pipeline of RNA Amplifiers, which have the potential to be game-changing for hundreds of genetic diseases.
- RNA Leaders USA Congress, Wednesday, September 6, 2023, Boston. Josh Mandel-Brehm, President & CEO, will deliver a presentation titled “Increasing Healthy Protein Levels to Address Genetic Diseases by Drugging RegRNAs” at 2:30 p.m. ET.
- Citi’s 18th Annual BioPharma Conference, Thursday, September 7, 2023, Boston. Josh Mandel-Brehm, President & CEO, and Kelly Gold, CFO, will participate in a fireside chat at 11:20 a.m. ET.
- UBS Biotechnology Private Company Virtual Symposium 2023, Wednesday, September 20, 2023. Kelly Gold, CFO, will participate in a fireside chat at 8:30 a.m. ET.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein can offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. Our RAP Platform™, which allows us to map regRNAs and select the optimal chemistry to generate safe and effective therapeutics, has the potential to address hundreds of genetic diseases across multiple tissues. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn.